Scientific Program
| Thursday, September 19, 2024 | |||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 08:30-09:00 | Welcome Coffee | ||
| 09:00-12:00 | Transplant Workshop | ||
| 12:00-12:45 | Lunch Break | ||
| 12:45-13:00 | Joint Meeting Opening Message |
||
| 13:00-14:30 | Session 1a: Indolent lymphoma |
13:00-14:30 | Session 1b: Controversies in lower risk MDS |
| Chair: Stefano Luminari, Italy | Moderators: Amer Zeidan, USA; Valeria Santini, Italy | ||
| 13:00-13:15 | Case Report | 13:00-13:15 | How do we define lower risk MDS in 2024? Matteo Della Porta, Italy |
| 13:15-13:30 | Q&A | 13:15-13:30 | Therapy of thrombocytopenic lower risk MDS? TBA |
| 13:30-13:50 | Marginal zone lymphoma (MZL): Luca Arcaini, Italy |
13:30-13:45 | What is the first line therapy for non-del5q anaemic LR-MDS: TBA |
| 13:50-14:10 | Follicular lymphoma (FL): TBA |
13:45-14:00 | Is sequencing or combining therapies the better approach for lower risk MDS? María Díez Campelo, Spain |
| 14:10-14:30 | Panel discussion: All session faculty | 14:00-14:15 | How should we measure therapeutic benefit in lower risk MDS? Pierre Fenaux, France |
| 14:15-14:30 | Panel discussion: All session faculty | ||
| 14:30-15:30 | Industry Symposium | Industry Symposium | |
| 15:30-16:00 | Coffee Break | ||
| 16:00-17:30 | Session 2a: Hodgkin lymphoma |
16:00-17:30 | Session 2b |
| Chair: Mehdi Hamadani, USA | |||
| 16:00-16:15 | Case Report | ||
| 16:15-16:30 | Q&A | ||
| 16:30-16:45 | 1st line treatment young/fit: Farrukh Awan, USA |
||
| 16:45-17:00 | 1st line treatment old/unfit: TBA |
||
| 17:00-17:15 | Best salvage in R/R Hodgkin: Nilanjan Ghosh, USA |
||
| 17:15-17:30 | Panel discussion: All session faculty | ||
| 17:30-18:30 | Industry Symposium | Industry Symposium | |
| 18:30-18:45 | Technical Break | ||
| 18:45-20:15 | Session 3a: Diffuse large B cell lymphoma (DLBCL) |
18:45-20:15 | Session 3b: Controversies in higher risk MDS |
| Chair: Anna Sureda, Spain | Moderators: Amer Zeidan, USA; Valeria Santini, Italy | ||
| 18:45-19:00 | Case Report | 18:45-19:00 | Should we care about MRD in higher risk MDS? Arjan van de Loosdrecht, Netherlands |
| 19:00-19:15 | Q&A | 19:00-19:15 | How can we stop phase 3 trials from failing in higher risk MDS? Lionel Adès, France |
| 19:15-19:30 | 1st line treatment: TBA |
19:15-19:30 | How does venetoclax fit in the management of higher risk MDS? Amer Zeidan, USA |
| 19:30-19:45 | Bispecific moAb: Catherine Thieblemont, France |
19:30-19:45 | Is immune checkpoint inhibition dead in higher-risk MDS and AML? Shahram Kordasti, UK |
| 19:45-20:00 | CAR T: TBA |
19:45-20:00 | Are oral HMAs a game changer in higher risk MDS? Valeria Santini, Italy |
| 20:00-20:15 | Panel discussion: All session faculty | 20:00-20:15 | Panel discussion: All session faculty |
| Friday, September 20, 2024 | |||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 07:30-08:00 | Welcome Coffee | ||
| 08:00-09:00 | IACH Plenary Lectures |
||
| 09:00-09:15 | Short Coffee Break | ||
| 09:15-10:45 | Industry Symposium | Industry Symposium | |
| 10:45-11:00 | Technical Break | ||
| 11:00-12:30 | Session 4a: T cell non-Hodgkin lymphoma (T-NHL) |
11:00-12:30 | Session 4b (MPNCo&D) |
| Chair: Mehdi Hamadani, USA | |||
| 11:00-11:15 | Case Report | ||
| 11:15-11:30 | Q&A | ||
| 11:30-11:50 | BV-CHP & beyond in 1st line T-NHL: Matthew Lunning, USA |
||
| 11:50-12:10 | Checkpoint inhibition or allografting for R/R NK/T-cell lymphomas: TBA |
||
| 12:10-12:30 | Panel discussion: All session faculty | ||
| 12:30-13:45 | Lunch Break | ||
| 13:45-14:45 | Industry Symposium | Industry Symposium | |
| 14:45-15:15 | Coffee Break | ||
| 15:15-16:45 | Session 5a: Chronic lymphocytic leukemia (CLL) |
15:15-16:45 | Session 5b: Controversies in classification, risk stratification and response assessment in AML |
| Chair: Mohamed Kharfan-Dabaja, USA | Moderator: Amer Zeidan, USA | ||
| 15:15-15:30 | Case Report | 15:15-15:30 | How do we risk stratify older patients with AML? Christoph Röllig, Germany |
| 15:30-15:45 | Q&A | 15:30-15:45 | What decisions should be made based on MRD in AML? Coleman Lindsley, USA |
| 15:45-16:05 | Front line therapy for CLL: Farrukh Awan, USA |
15:45-16:00 | Can (or should) response criteria of MDS and AML be harmonized? Lisa Pleyer, Austria |
| 16:05-16:25 | Transplant and cellular therapies in CLL: TBA |
16:00-16:15 | Should we have two pathologic systems for AML? TBA |
| 16:25-16:45 | Panel discussion: All session faculty | 16:15-16:45 | Panel discussion: All session faculty |
| 16:45-17:00 | Short Coffee Break | ||
| 17:00-18:30 | Session 6a: Minimal residual disease (MRD) |
Session 6b (MPNCo&D) |
|
| Chair: Stefano Luminari, Italy | |||
| 17:00-17:15 | Case Report | ||
| 17:15-17:30 | Q&A | ||
| 17:30-17:45 | Positron emission tomography (PET): TBA |
||
| 17:45-18:00 | Mantle cell lymphoma (MCL): TBA |
||
| 18:00-18:15 | Follicular lymphoma (FL): TBA |
||
| 18:15-18:30 | Panel discussion: All session faculty | ||
| 18:30-19:00 | IACH Awards |
||
| Saturday, September 21, 2024 | |||
| Hall A IACH + COLYM |
Hall B COMydAL + MPNCo&D |
||
| 07:30-08:00 | Welcome Coffee | ||
| 08:00-09:30 | Session 7a: Mantle cell lymphoma (MCL) |
08:00-09:30 | Session 7b: Controversies in the management of AML |
| Chair: Mohamed Kharfan-Dabaja, USA | Moderator: Amer Zeidan, USA | ||
| 08:00-08:15 | Case Report | 08:00-08:15 | Doublets vs triplets in older AML patients? Stephane De Botton, France |
| 08:15-08:30 | Q&A | 08:15-08:30 | Which AML patients should we transplant in 2024? TBA |
| 08:30-08:50 | What is new in front-line management? TBA |
08:30-08:45 | What to do with TP53 mutated higher risk MDS/AML? Maximiian Stahl, USA |
| 08:50-09:10 | Management of relapsed and/or refractory MCL: Amer Beitinjaneh, USA |
08:45-09:00 | Targeting novel mechanisms of resistance in AML: TBA |
| 09:10-09:30 | Panel discussion: All session faculty | 09:00-09:15 | Should we use maintenance therapy post-transplant? TBA |
| 09:15-09:30 | Panel discussion: All session faculty | ||
| 09:30-11:00 | Industry Symposium | Industry Symposium | |
| 11:00-11:30 | Coffee Break | ||
| 11:30-13:00 | Session 8a: Rare diseases |
Session 8b (MPNCo&D) | |
| Chair: Anna Sureda, Spain | |||
| 11:30-11:45 | Case Report | ||
| 11:45-12:00 | Q&A | ||
| 12:00-12:20 | Post-transplant lymphoproliferative disorders (PTLD): TBA |
||
| 12:20-12:40 | Richter’s transformation: TBA |
||
| 12:40-13:00 | Panel discussion: All session faculty | ||
| 13:00-13:45 | Lunch Break | ||
| 13:45-14:45 | Industry Symposium | Industry Symposium | |
| 14:45-15:00 | Technical Break | ||
| 15:00-17:00 | Session 9a: IACH Lectures |
||
| 17:00-17:15 | Joint Meeting Closing Remarks |
||